Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Phosphorus containing other than solely as part of an...
Reexamination Certificate
2008-05-06
2008-05-06
Crane, L. E. (Department: 1623)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Phosphorus containing other than solely as part of an...
C514S365000, C514S649000, C514S665000, C514S706000
Reexamination Certificate
active
11351166
ABSTRACT:
The present invention provides methods of administering amifostine, WR-1065, or a combination thereof, to patients receiving radiation therapy or chemotherapy in a manner that significantly reduces or decreases the adverse or undesirable side-effects of the compounds as compared with conventional intravenous administration.
REFERENCES:
patent: 3892824 (1975-07-01), Piper et al.
patent: 4656034 (1987-04-01), Sarnoff
patent: 5091180 (1992-02-01), Walker et al.
patent: 5167947 (1992-12-01), Geary
patent: 5217964 (1993-06-01), Edwards et al.
patent: 5424471 (1995-06-01), Kennedy et al.
patent: 5434145 (1995-07-01), Edwards et al.
patent: 5466678 (1995-11-01), Kawabata et al.
patent: 5488042 (1996-01-01), Grdina
patent: 5567686 (1996-10-01), Grdina
patent: 5591731 (1997-01-01), Kennedy et al.
patent: 5605931 (1997-02-01), Hanson
patent: 5618823 (1997-04-01), Cavalletti et al.
patent: 5807744 (1998-09-01), Berneman et al.
patent: 5846958 (1998-12-01), Capizzi et al.
patent: 5869338 (1999-02-01), Grdina
patent: 5891856 (1999-04-01), Grdina
patent: 5972986 (1999-10-01), Seibert et al.
patent: 5994409 (1999-11-01), Stogniew et al.
patent: 6028114 (2000-02-01), Quash
patent: 6051563 (2000-04-01), Stogniew et al.
patent: 6054622 (2000-04-01), Zhang et al.
patent: 6066668 (2000-05-01), Hausheer
patent: 6075053 (2000-06-01), Hausheer
patent: 6114394 (2000-09-01), Edwards et al.
patent: 6127351 (2000-10-01), Stogniew et al.
patent: 6218377 (2001-04-01), Stogniew et al.
patent: 6489312 (2002-12-01), Stogniew et al.
patent: 6573253 (2003-06-01), Stogniew
patent: 7053072 (2006-05-01), Cassatt et al.
patent: WO 89/05637 (1989-06-01), None
patent: WO 89/07942 (1989-09-01), None
patent: WO 90/14007 (1990-11-01), None
patent: WO 94/22307 (1994-10-01), None
patent: WO 96/25045 (1996-08-01), None
patent: WO 97/11666 (1997-04-01), None
patent: WO 98/34622 (1998-08-01), None
patent: WO 99/30705 (1999-06-01), None
patent: WO 00/56299 (2000-09-01), None
patent: WO 02/062350 (2002-08-01), None
[R] Capizzi, “The Preclinical Basis for Broad-Spectrum Selective Cytoprotection of Normal Tissues Froqm Cytotoxic Therapies by Amifostine (Ethylol™).,” □□European Journal of Cancer, 37A(Suppl. 4), S5-S16 (1996).
(S) Korst et al., “Pharmacokinetics of Amifostine and its Metabolites in Patients,” □□European Journal of Cancer, 33(9), 1425-1429 (Aug. 1997).
Betticher et al., 1995, “Carboplatin combined with amifostine, a bone marrow protectant, in the treatment of non-small-cell lung cancer: a randomised phase II study,” Br. J. Cancer 5: 1551-1555.
Bohuslavizki, K.H., et al., May 1997, “Protective Effect of Amifostine on Salivary Glands of Rabbits Treated With High Dose of Iodine-131,” Scientific Abstracts of the 44th Annual Meeting of the Society of Nuclear Medicine, San Antonio, Texas, June. 1-5, 1997, No. 950; Journal of Nuclear Medicine 38(5) May 1997 Suppl.
Bohuslavizki et al., 1997, “Protection of salivary glands by amifostine in patients treated with high dose radioiodine”, Eu. Jour. Cancer 33: S17, Abstr. No. 59.
Boven et al., 2002, “BNP7787, a novel protector against platinum-related toxicities, does not affect the efficacy of cisplatin or carboplatine in human tumour xenografts”, Eur. J. Cancer 38: 1148-1156.
Brizel et al., 2000, “Phase III Randomized Trial of Amifostine as a Radioprotector in Head and Neck Cancer,” Journal of Clinical Oncology 18(19): 3339-3345.
Buntzel et al., 1998, “Selective cytoprotection with amifostine in concurrent radiochemotherapy for head and neck cancer”, Ann Oncol 9: 505-509.
Buntzel, J. et al., 1998, “Radiochemotherapy With Amifostine Cytoprotection For Head and Neck Cancer” Support Care Cancer 6:155-160.
Buntzel, J. , 1998, “Intensification of Radiochemistry With Amifostine in Head and Neck Cancer”, P Ann M Am Soc. vol. 17 Abstract No. 1555 at p. 403a.
Buntzel J. et al., 1997 “Selective cytoprotection with amifostine: A new strategy in supportive care of head and neck malignancies”, Oto-Rhino Laryngologia Nova 7(5-6): 276-280.
Buntzel et al., 1996, “Ethyol® (Amifostine) Provides Multilineage Hematoprotection and Protection Against Non-Hematologic Toxicities Induced by Radiochemotherapy (RCT) of Head and Neck Cancer,” Blood 88(Supp. 1): p. 448a, Abstr No. 1781.
Buntzel et al., 1997, “Amifostine in Simultaneous Radiochemotherapy of Head and Neck Cancer”, Oto-Rhino-Laryngologia Nova 7(4): 204-210.
Buntzel et al., 1997, “Intensive Radiochemotherapy (RCT) with Amifostine (A) in Head and Neck (H & N) Cancer”, Eur. J. Cancer 33(Suppl. 8): S17-S18 , Abstr. No. 61.
Busch, B. et al., 1997, “Cytoprotection With Amifostine in Recurrent Head and Neck Cancer,” Abstract, No. 1418, Proceedings of ASCO, vol. 16. 397a, Abstr No. 1418.
Caldwell, R.W. and Heiffer, M.H., 1975, “Acute Cardiovascular and Autonomic Effects of WR-2721: A Radioprotective Compound”, Radiation Research 62:62-69.
Constine, et al. Aug. 1986, “Protection by WR-2721 of Human Bone Marrow Function Following Irradiation,” Int. J. Radiation Oncology Biol. Phys., 12(8):1505-1508.
Culy et al., 2001, “Amifostine: An Update on its clinical status as a cytoprotectant in patients with cancer receiving chemotherapy or radiotherapy and its potential therapeutic application in myelodyplastic syndrome”, Drugs 61(5): 641-684.
Dorr et al., 1995, “Selective Cardioprotection of Rat Heart Myocytes Exposed to DNA Intercalating Agents Using Amifostine (AMI) and its Dephosphorylated Metabolite, WR-1065,” Eur. J. Cancer 31A(Supp. 5): S123(579).
Doz et al., 1991, “Experimental Basis for Increasing the Therapeutic Index of Carboplatin in Brain Tumor Therapy by Pretreatment With WR-Compounds”, Cancer Chemother. Pharmacol. 28:308.
Foster-Nora et al., 1997, “Amifostine for protection from antineoplastic drug toxicity”, Am. Jour. Health-system Pharm. 54(7): 787-800.
Grdina et al., 1985, “The Radioprotector WR-1065 Reduces Radiation-Induced Mutations of the Hyproxanthine-Guanine Phosphoribosye Transferase Locus in V79 Cells”, Carcinogenesis (London) 6:929-931.
Grdina, J. & Sigdestad, C., 1989, “Radiation Protectors: The Unexpected Benefits”, Drug Metab. Rev. 20(1):13-42.
Hensely et al., 1999, American Society of Clinical Oncology Clinical Practice Guidelines for the Use of Chemotherapy and Radiochemistry Protectants, 17(10):3333-3355.
Kemp et al., 1996, “Amifostine Pretreatment of Protection Against Cyclophosamide-induced and Cisplatin-induced Toxicities: Results of a Randomized Control Trial in Patient with Advanced Ovarian Cancer”, J. Clin. Oncology 14:2101-2112.
McDonald, S. et al., 1995, “Amifostine Preserves The Salivery Gland Function During Irradiation of the Head and Neck,” ECCO 8 Paris-Oct. 29-Nov. 2, 1995, The European Journal of Cancer, vol. 31A, Supplement 5, Poster 415.
Phillips and Wasserman, 1984, “Promise of Radiosensitizers and Radioprotectors in the Treatment of Human Cancer,” Cancer Treat. Rep. 68:291-302.
Savoye, C. et al., 1997, “Thiol WR-1065 and disulphide WR-33278, two metabolites of the drug Ethyol (Wr-2721), protect DNA against fast neutron-induced strand breadage”, Int. J. Radiat. Biol. 71(2):193-202.
Spencer et al., 1995, “Amifostine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential as a radioprotector and cytotoxic chemoprotector”, Drugs 50(6): 1001-1031.
Takahashi, I., et al., Jun. 1986, “Clinical Study of the Radioprotective Effects of Amifostine (YM-08310, WR-2721) on Chronic Radiation Injury,” Int. J. Radiation Oncology Biol. Phys. 12(6): 935-938.
Tannehill, S.P., et al., Aug. 1996, “Amifostine and Radiation Therapy: Past, Present and Future,” Seminars in Oncology 23(No. 4, Suppl. 8): 69-77.
Tannehill, S.P., et al., Aug.
Cassatt David
Fazenbaker Christine A.
Crane L. E.
Jones Day
Medimmune Oncology Inc.
LandOfFree
Methods for the administration of amifostine and related... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Methods for the administration of amifostine and related..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods for the administration of amifostine and related... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3955817